Priming Solution News Today

/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, announces that eight...

Study demonstrated safety and tolerability of H-Guard®, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis.Encouraging biomarker data positions H-Guard for upcoming Acute Kidney Injury (AKI) trial focused on reducing complement mediated renal tubu...

/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and...

/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, is pleased...

/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today...

/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today...

/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that...

Invizius Limited, a Motherwell, Scotland, UK-based biotechnology company developing treatments to suppress unwanted innate immune responses, closed Series A financing of £5.3m. The round was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. The Series A remains open to other investors until June 2021. The company inten...

Share this article Share this article MOTHERWELL, Scotland, May 6, 2021 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of £5.3 million. The financing was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and inves...